News
Select year:
2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016
Click here for announcements regarding managers transactions.
Click here for news in Danish.
December 21, 2018 | Company Announcements
Bavarian Nordic Announces FDA Acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox VaccineNovember 13, 2018 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back ProgramNovember 09, 2018 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2018 November 02, 2018 | Company Announcements
Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic CancersNovember 01, 2018 | Company Announcements
Bavarian Nordic Announces Initiation of Phase 2 Trial of BN-Brachyury for the Treatment of Chordoma November 01, 2018 | Company Announcements
Henrik Juuel Joins Bavarian Nordic as Chief Financial OfficerSeptember 18, 2018 | Company Announcements
Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder CancerAugust 16, 2018 | Company Announcements
Bavarian Nordic Announces First Half 2018 Results August 09, 2018 | Company Announcements
Bavarian Nordic Granted EUR 30 Million Loan from The European Investment BankAugust 08, 2018 | Company Announcements
Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV VaccineJuly 11, 2018 | Company Announcements
Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal CancerJune 07, 2018 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise May 31, 2018 | Company Announcements
Bavarian Nordic Announces Appointment of Henrik Juuel as Chief Financial OfficerMay 24, 2018 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2018 May 02, 2018 | Company Announcements
Bavarian Nordic Receives FDA Orphan Drug Designation for BN-Brachyury for the Treatment of ChordomaApril 17, 2018 | Company Announcements
Bavarian Nordic A/S – Report on the Results of the Annual General Meeting, held April 17, 2018March 26, 2018 | Company Announcements
Bavarian Nordic A/S – Notice Convening Ordinary General Meeting March 16, 2018 | Company Announcements
Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis VirusMarch 12, 2018 | Company Announcements
Bavarian Nordic Awards Restricted Stock Units to Executive ManagementMarch 12, 2018 | Company Announcements
Bavarian Nordic Announces Annual Report 2017 March 08, 2018 | Company Announcements
Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal CancerMarch 06, 2018 | Company Announcements
Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV VaccineFebruary 26, 2018 | Company Announcements
Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic CancersFebruary 06, 2018 | Company Announcements
Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine January 31, 2018 | Company Announcements
Bavarian Nordic Announces the Planned Departure of Chief Financial Officer, Ole Larsen